PM 01183: Clinical Trials

13 trials of PM 01183, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 3 active not recruiting, 3 completed, 2 not yet recruiting. 13 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 313Recruiting 5, Active not recruiting 3, Completed 3, Not yet recruiting 2

Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer
Phase 3Not yet recruitingZai Lab (Shanghai) Co., Ltd.5302026-12-312026-08-31
A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)
Ris-Rez, Atezolizumab, Etoposide - Lung Neoplasm
Phase 3Not yet recruitingGlaxoSmithKline7002026-12-252026-11-18
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
Phase 3RecruitingSystImmune Inc.5502026-08-042026-11-12
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer
Phase 3RecruitingAbbVie5312026-07-022026-09-23
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 3RecruitingGilead Sciences6952025-04-042026-10-20
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Lurbinectedin, Irinotecan, Topotecan - Relapsed Small Cell Lung Cancer
Phase 3RecruitingLuye Pharma Group Ltd.1802024-09-142024-12-12
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer
Phase 3RecruitingDaiichi Sankyo5402024-05-212026-08-06
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Lurbinectedin, Doxorubicin - Leiomyosarcoma
Phase 3Active not recruitingPharmaMar4692023-09-212026-06-18
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Tarlatamab, Lurbinectedin, Topotecan - Small Cell Lung Cancer (SCLC)
Phase 3Active not recruitingAmgen5092023-05-312026-01-05
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Irinotecan, Lurbinectedin, Topotecan - Relapsed Small Cell Lung Cancer
Phase 3CompletedPharmaMar7052022-07-222026-10-21
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Atezolizumab, Lurbinectedin, Carboplatin - Small-Cell Lung Cancer
Phase 3Active not recruitingHoffmann-La Roche6602021-11-182026-09-09
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX) - Small-cell Lung Cancer
Phase 3CompletedPharmaMar6132016-08-302021-10-28
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan - Ovarian Cancer
Phase 3CompletedPharmaMar4422015-05-012020-04-03

Conditions studied

Small Cell Lung Carcinoma (10)  ·  Lung Neoplasms (2)  ·  Neoplasms (2)  ·  Carcinoma, Small Cell (1)  ·  Leiomyosarcoma (1)  ·  Ovarian Neoplasms (1)

Sponsors

PharmaMar (4)  ·  AbbVie (1)  ·  Amgen (1)  ·  Daiichi Sankyo (1)  ·  Gilead Sciences (1)  ·  GlaxoSmithKline (1)  ·  Hoffmann-La Roche (1)  ·  Luye Pharma Group Ltd. (1)  ·  SystImmune Inc. (1)  ·  Zai Lab (Shanghai) Co., Ltd. (1)

Countries

United States (10)  ·  Germany (9)  ·  Spain (9)  ·  Belgium (8)  ·  France (8)  ·  Italy (8)  ·  Poland (8)  ·  Greece (7)  ·  Hungary (7)  ·  Austria (6)  ·  Brazil (6)  ·  Canada (6)  ·  South Korea (6)  ·  United Kingdom (6)  ·  Australia (5)

Top investigators

Junliang Cai, MD (1)  ·  Ying Chen, Doctor (1)

Results publications

PMID 34521554, PMID 36252599, PMID 37407274, PMID 39530627, PMID 39932221, PMID 40473449, PMID 40963055, PMID 41055143, PMID 42377743

NIH funding

2023 (2), 2025 (1)